Welcome to our dedicated page for Pro-Dex Colo news (Ticker: PDEX), a resource for investors and traders seeking the latest updates and insights on Pro-Dex Colo stock.
Pro-Dex, Inc. reports developments tied to its design, development, and manufacture of powered surgical instruments, including autoclavable, battery-powered and electric multi-function surgical drivers and shavers used primarily in orthopedic, thoracic, and maxocranial facial markets. Company updates frequently address shipments of orthopedic handpieces, repair revenue, CMF drivers and batteries, engineering and regulatory services, and customer concentration around its largest medical-device customer.
Recurring news also includes quarterly operating results, contract amendments, product mix, manufacturing capacity, and corporate actions. The completed acquisition of Advanced Precision Machining LLC added a wholly owned machining subsidiary that produces machined components and sub-assemblies for medical device, aerospace, and defense-related customers.
Pro-Dex, Inc. (NasdaqCM:PDEX) reported its fiscal 2022 fourth quarter and full-year results on August 25, 2022, showing a 34% increase in quarterly net sales to $12.6 million. Annual net sales rose 11% to $42.0 million, driven mainly by orthopedic device sales. However, gross profit decreased 3% year-over-year to $13.1 million, while net income for the year was $3.9 million, down from $5.8 million. Operating expenses decreased 12% due to reduced R&D costs. Supply chain disruptions were noted, but the company remains optimistic about future growth.
Pro-Dex reported Q3 fiscal 2022 results, revealing a 21% decline in net sales, totaling $9.3 million, primarily due to decreased thoracic driver sales. Gross profit fell 35% to $2.9 million, attributed to increased component costs amid supply chain challenges. Operating expenses decreased 27% to $1.9 million. Net income dropped 78% to $462,000 or $0.12 per diluted share. However, year-to-date sales increased 3% to $29.4 million. CEO Van Kirk expressed optimism for Q4, citing a healthy backlog and secured components.
Pro-Dex, Inc. (NASDAQ:PDEX) reported a robust fiscal 2022 second quarter with net sales up 23% to $10.2 million, driven by orthopedic surgical handpiece sales. Gross profit rose 31% to $3.4 million, and operating expenses declined by 13% to $1.8 million. However, net income fell to $925,000 ($0.25 per diluted share) compared to $1.8 million ($0.44) from the same quarter last year. Looking ahead, Pro-Dex warns of supply chain challenges that could reduce net sales in the upcoming quarters but remains optimistic about long-term prospects.
Pro-Dex, Inc. (NasdaqCM:PDEX) reported a 16% increase in net sales for Q1 fiscal 2022, totaling $10.0 million compared to $8.6 million in Q1 2021. The growth stemmed from higher sales of surgical handpieces and CMF drivers, though sales of a thoracic driver decreased. Gross profit fell by $47,000, with a margin of 34% down from 40%. Operating expenses rose $184,000, while net income decreased to $1.1 million, or $0.28 per share. The company is advancing internal projects and preparing to relocate employees to a new facility.
Pro-Dex reported Q4 2021 net sales of $9.4 million, a 15% decrease from $11.1 million in Q4 2020, primarily due to lower medical device sales following two previous product launches. Gross profit fell by 27% to $3.1 million, driven by decreased sales and price concessions. Operating expenses increased by 21% to $2.5 million. Yearly results showed a 9% sales increase to $38 million, with a slight gross profit rise to $13.6 million. However, net income for the year decreased to $4.5 million from $6.1 million, attributed to higher operating expenses and R&D investments.
Pro-Dex reported a 38% increase in net sales for Q3 FY2021, reaching $11.7 million, driven by strong performance in thoracic drivers. Gross profit also rose 37% to $4.4 million. Net income increased to $2.0 million ($0.50 per diluted share) from $1.2 million ($0.30 per diluted share) year-over-year. However, operating expenses surged by 67% due to heightened investment in product development. For the nine months ended March 31, 2021, sales rose 21% to $28.6 million, with net income stable at $3.6 million. The CEO expressed pride in team performance amid challenges during the pandemic.
Pro-Dex, Inc. (NASDAQ:PDEX) reported a 4% increase in net sales for the second quarter of fiscal 2021, totaling $8.3 million, driven by new product sales. However, gross profit declined 9% to $2.6 million due to under-absorbed fixed manufacturing costs. Operating expenses surged 74% to $2.1 million as the company invested in R&D and administrative functions. Net income fell to $337,000 or $0.08 per diluted share, down from $1.2 million or $0.31 per diluted share a year earlier. Year-to-date net sales grew 11% to $16.9 million.
Pro-Dex reported a 19% increase in net sales for Q1 fiscal 2021, totaling $8.6 million, up from $7.2 million in Q1 fiscal 2020. The gross profit rose 25% to $3.5 million, with a gross margin of 40%. Operating expenses increased by $637,000, reflecting investments in R&D for new product launches. Net income for the quarter was $1.3 million, or $0.32 per diluted share, compared to $1.1 million or $0.27 in the prior year. CEO Richard Van Kirk expressed optimism about future product releases, including a new ENT shaver and CMF driver.
Pro-Dex, Inc. (NASDAQ:PDEX) reported a significant increase in net sales for Q4 2020, rising 59% to $11.1 million, attributed to new product launches and a $1.7 million increase in revenue from its largest customer. Gross profit surged 69%, reaching $4.3 million, while net income rose to $2.5 million, or $0.64 per diluted share. For the fiscal year, net sales were up 28% at $34.8 million, with net income increasing to $6.1 million. Operating expenses also grew by 27%, reflecting higher personnel costs. The company maintains a cautious outlook amid the ongoing COVID-19 pandemic.